What is the recommended approach to evaluate a suspected insulinoma?

Insulinoma Evaluation

For suspected insulinoma, establish biochemical diagnosis with a supervised 72-hour fast measuring plasma glucose, insulin, C-peptide, and proinsulin, followed by localization using CT or MRI combined with endoscopic ultrasound (EUS), reserving intraoperative ultrasound (IOUS) as the definitive localization method during surgery 1.

Biochemical Diagnosis

The diagnostic evaluation must first confirm endogenous hyperinsulinemic hypoglycemia before pursuing localization studies. The supervised prolonged fast remains the gold standard 1.

Supervised 72-Hour Fast Protocol

• Continue fasting until Whipple's triad is documented OR plasma glucose falls below 55 mg/dL (3.0 mmol/L) 1
• Measure plasma glucose with a precise laboratory method, not fingerstick glucose monitoring 1
• Most patients (approximately two-thirds) with insulinoma will meet diagnostic criteria within 24 hours, and the vast majority within 48 hours 1
• A progressive rise in β-hydroxybutyrate levels signals a negative fast and can be used to terminate the test 1

Critical Biochemical Markers at Time of Hypoglycemia

Diagnostic criteria for insulinoma include 1:

• Plasma insulin ≥3 μU/mL (18 pmol/L) - met in 29 of 32 patients in one series
• Plasma C-peptide ≥0.6 ng/mL (0.2 nmol/L) - met in all 32 patients
• Plasma proinsulin ≥5.0 pmol/L - met in all 32 patients
• Plasma β-hydroxybutyrate ≤2.7 mmol/L (provides biological evidence of insulin excess)
• Plasma glucose increase ≥25 mg/dL (1.4 mmol/L) after IV glucagon (indicates preserved hepatic glycogen stores)

Important caveat: C-peptide and proinsulin are more sensitive than insulin alone, as some insulinoma patients may have insulin levels below 3 μU/mL but still have elevated C-peptide and proinsulin 1. Elevated proinsulin after excluding uremia, hepatic cirrhosis, thyrotoxicosis, and exogenous insulin/sulfonylurea administration strongly indicates organic hyperinsulinemia 2.

Tumor Localization

Once biochemical diagnosis is established, proceed with anatomic localization. The evidence shows significant variation in preoperative imaging sensitivity, with intraoperative methods proving superior.

Recommended Preoperative Imaging Sequence

First-line imaging: CT or MRI of the pancreas

• CT sensitivity ranges from 29-44% in older studies 3, 4
• MRI sensitivity reaches 57-77% 4
• CT combined with MRI achieves 96.87% diagnostic rate 5

Second-line imaging: Endoscopic ultrasound (EUS)

• EUS demonstrates 91.6% sensitivity and positive predictive value 6
• Particularly valuable when CT/MRI are negative or discordant 7

Emerging modality: 68Ga-Exendin-4 PET-CT or 68Ga-DOTATOC PET-CT

• 100% sensitivity in recent series 6
• Successfully localizes tumors when multiphasic CT is normal 6
• 91.6% positive predictive value 6
• May offer added value in selected cases with negative conventional imaging 7

Preoperative Localization Limitations

A critical pitfall: No single preoperative imaging modality is reliable enough to exclude surgery 4. Preoperative imaging sensitivity is considerably inferior to intraoperative findings 3. In one analysis, the comprehensive waste of non-diagnostic preoperative studies equaled 43.7% of resources utilized 3.

Intraoperative Localization

Intraoperative ultrasound (IOUS) combined with surgical palpation represents the definitive localization method 3, 4.

Intraoperative Approach

• IOUS sensitivity: 96.6-100% 3, 4
• Surgical palpation sensitivity: 88.2-96% 8, 4
• IOUS should be performed in all cases where the tumor is not immediately apparent 4
• The combination of surgical exploration with IOUS is superior to any preoperative imaging modality 3

Key recommendation from research: Surgery with IOUS, preceded by only one preoperative diagnostic imaging technique, represents the best approach for establishing diagnosis and treating insulinomas 3. This challenges the traditional approach of exhaustive preoperative localization studies.

Special Considerations

Atypical Pathologies

Be aware of islet cell hyperplasia as a cause of hyperinsulinemic hypoglycemia 7. This can result in:

• Persistent hypoglycemia despite surgical resection
• Need for ongoing medical therapy
• Altered surgical planning and outcomes

MEN-1 Syndrome

Five to 10% of insulinomas occur with multiple endocrine neoplasia type 1 syndrome 9. Screen for MEN-1 in patients with:

• Multiple pancreatic lesions
• Family history of endocrine tumors
• Other endocrine manifestations

Postprandial Hypoglycemia

For patients with suspected postprandial (rather than fasting) hypoglycemia 1:

• Perform a mixed-meal test over 5 hours with components recognized by the patient as triggering symptoms
• Never use oral glucose tolerance test for evaluating postprandial hypoglycemia 1
• Apply the same biochemical criteria developed for fasting conditions

Practical Algorithm

1. Document Whipple's triad with supervised fast (up to 72 hours)
2. Obtain critical labs at time of hypoglycemia: glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate
3. If biochemical criteria met, proceed to imaging with CT or MRI (or both for highest yield)
4. If CT/MRI negative or equivocal, obtain EUS or consider 68Ga-Exendin-4 PET-CT
5. Proceed to surgery with planned IOUS regardless of preoperative localization success
6. Use IOUS and surgical palpation as definitive localization during operation

This algorithmic approach prioritizes definitive biochemical diagnosis first, uses selective preoperative imaging to guide surgical planning, and relies on superior intraoperative localization techniques for definitive tumor identification and curative resection.